The substance being tested, called coenzyme Q10, is produced naturally in the body and is an important link in the chain of chemical reactions that produce energy in mitochondria, the “powerhouses” of cells.
The enzyme is also a potent antioxidant – a chemical that “mops up” potentially harmful chemicals generated during normal metabolism.
“At present, the very best therapies we have for
Many past studies have shown that
Moreover, laboratory research has demonstrated that coenzyme Q10 can protect the area of the brain damaged in
The Phase III clinical trial, a large, randomized study with a control group, follows an earlier investigation that tested several doses of coenzyme Q10 in a small group of patients with early-stage Parkinson’s disease.
The highest dose, 1,200 mg, appeared promising-over the course of 16 months, patients taking this dose experienced significantly less decline than other patients in motor (movement) function and ability to carry out activities of daily living, such as feeding or dressing themselves.
In the present trial, 600 patients will be enrolled at 60 centers in the U.S. and Canada.
Two dosages of coenzyme Q10 are being tested,1,200 mg and 2,400 mg, delivered in maple nut-flavored chewable wafers that also contain vitamin E.
Participants in the study will be evaluated periodically over 16 months for symptoms of Parkinson’s disease, including tremor, stiffness of the limbs and trunk, impaired balance and coordination, and slowing of movements.
They will also be assessed for ability to perform daily activities, overall quality of life, and need to take medications to alleviate symptoms.